[{"group":["NCT04119440"],"end":"2020-05-01","className":["December 2021"],"title":"green","6":"Low Dose, Phase 1, MERS (Middle East Respiratory Syndrome)","id":1},{"group":["NCT04244591"],"end":"2020-01-26","className":["December 25, 2020"],"title":"green","6":"standard care, Phase 2/Phase 3, Coronavirus Infections","id":2},{"group":["NCT04244591"],"end":"2020-01-26","className":["December 25, 2020"],"title":"green","6":"standard care, Phase 2/Phase 3, Respiratory Infection Virus","id":3},{"group":["NCT04245631"],"end":"2020-01-01","className":["December 31, 2020"],"title":"green","6":"RAA assay for 2019-nCoV, N/A, New Coronavirus","id":4},{"group":["NCT04251767"],"end":"2020-02-05","className":["April 30, 2020"],"title":"green","6":"Observational group, N/A, COVID-19 Complicated With Refractory Intestinal Infections","id":5},{"group":["NCT04251871"],"end":"2020-01-22","className":["January 22, 2021"],"title":"green","6":"Conventional medicines and TCMs granules, N/A, Pneumonia Caused by Human Coronavirus (Disorder)","id":6},{"group":["NCT04252118"],"end":"2020-01-27","className":["December 2021"],"title":"green","6":"MSCs Treatment Group, Phase 1, 2019 Novel Coronavirus Pneumonia","id":7},{"group":["NCT04252274"],"end":"2020-01-30","className":["December 31, 2020"],"title":"blue","6":"Darunavir, Cobicistat and conventional treatments, Phase 3, Pneumonia, Pneumocystis","id":8},{"group":["NCT04252274"],"end":"2020-01-30","className":["December 31, 2020"],"title":"blue","6":"Darunavir, Cobicistat and conventional treatments, Phase 3, Coronavirus","id":9},{"group":["NCT04252885"],"end":"2020-01-28","className":["July 31, 2020"],"title":"green","6":"Group A-Standard treatment+lopinavir/ritonavir, Phase 4, Coronavirus Infections","id":10},{"group":["NCT04255940"],"end":"2020-01-20","className":["April 30, 2020"],"title":"green","6":"After outbreak, N/A, Cardiovascular Death; Major Adverse Cardiovascular Events","id":11},{"group":["NCT04256395"],"end":"2020-02-01","className":["July 31, 2020"],"title":"green","6":"NULL, N/A, Susceptibility to Viral and Mycobacterial Infection","id":12},{"group":["NCT04259892"],"end":"2020-02-04","className":["February 4, 2021"],"title":"green","6":"NULL, N/A, Coronavirus","id":13},{"group":["NCT04260308"],"end":"2020-02-03","className":["April 20, 2020"],"title":"green","6":"residents, N/A, Virus; Pneumonia","id":14},{"group":["NCT04260594"],"end":"2020-02-07","className":["December 30, 2020"],"title":"green","6":"Arbidol tablets + basic treatment, Phase 4, 2019-nCoV","id":15},{"group":["NCT04261517"],"end":"2020-02-06","className":["December 31, 2020"],"title":"blue","6":"Hydroxychloroquine and conventional treatments, Phase 3, Pneumonia, Pneumocystis","id":16},{"group":["NCT04261517"],"end":"2020-02-06","className":["December 31, 2020"],"title":"blue","6":"Hydroxychloroquine and conventional treatments, Phase 3, Coronavirus","id":17},{"group":["NCT04261907"],"end":"2020-02-07","className":["June 30, 2020"],"title":"green","6":"ASC09/ritonavir group, N/A, 2019-nCoV","id":18},{"group":["NCT04262921"],"end":"2020-02-07","className":["August 7, 2023"],"title":"green","6":"NULL, N/A, Coronavirus Infections","id":19},{"group":["NCT04264533"],"end":"2020-02-14","className":["September 30, 2020"],"title":"red","6":"VC, Phase 2, Vitamin C","id":20},{"group":["NCT04264533"],"end":"2020-02-14","className":["September 30, 2020"],"title":"red","6":"VC, Phase 2, Pneumonia, Viral","id":21},{"group":["NCT04264533"],"end":"2020-02-14","className":["September 30, 2020"],"title":"red","6":"VC, Phase 2, Pneumonia, Ventilator-Associated","id":22},{"group":["NCT04269525"],"end":"2020-02-06","className":["September 30, 2020"],"title":"red","6":"pneumonia, Phase 2, Pneumonia, Viral","id":23},{"group":["NCT04269525"],"end":"2020-02-06","className":["September 30, 2020"],"title":"red","6":"pneumonia, Phase 2, Pneumonia, Ventilator-Associated","id":24},{"group":["NCT04272710"],"end":"2020-01-25","className":["April 30, 2020"],"title":"green","6":"ACEI treatment, N/A, 2019-nCoV","id":25},{"group":["NCT04273321"],"end":"2020-02-14","className":["May 30, 2020"],"title":"green","6":"Pred group, N/A, COVID-19","id":26},{"group":["NCT04273321"],"end":"2020-02-14","className":["May 30, 2020"],"title":"green","6":"Pred group, N/A, Novel Coronavirus Pneumonia","id":27},{"group":["NCT04273529"],"end":"2020-02-20","className":["June 30, 2020"],"title":"red","6":"Control group, Phase 2, COVID-19 Thalidomide","id":28},{"group":["NCT04273581"],"end":"2020-02-18","className":["May 30, 2020"],"title":"red","6":"Control group, Phase 2, COVID-19 Thalidomide","id":29},{"group":["NCT04273646"],"end":"2020-02-16","className":["February 15, 2022"],"title":"green","6":"UC-MSCs Treatment Group, N/A, 2019 Novel Coronavirus Pneumonia","id":30},{"group":["NCT04273646"],"end":"2020-02-16","className":["February 15, 2022"],"title":"green","6":"UC-MSCs Treatment Group, N/A, COVID-19","id":31},{"group":["NCT04273763"],"end":"2020-02-16","className":["April 30, 2020"],"title":"green","6":"Group A, N/A, Novel Coronavirus Pneumonia","id":32},{"group":["NCT04273763"],"end":"2020-02-16","className":["April 30, 2020"],"title":"green","6":"Group A, N/A, 2019-nCoV","id":33},{"group":["NCT04274322"],"end":"2020-02-01","className":["July 2020"],"title":"green","6":"Cohort 1, N/A, Critically Ill","id":34},{"group":["NCT04274322"],"end":"2020-02-01","className":["July 2020"],"title":"green","6":"Cohort 1, N/A, Coronavirus Infections","id":35},{"group":["NCT04275388"],"end":"2020-02-14","className":["December 14, 2021"],"title":"green","6":"Xiyanping injection +other drugs, N/A, 2019 Novel Coronavirus Pneumonia","id":36},{"group":["NCT04275414"],"end":"2020-02-01","className":["May 2020"],"title":"green","6":"bevacizumab plus regular therapy, Phase 2/Phase 3, Coronavirus Infections","id":37},{"group":["NCT04275947"],"end":"2020-02-14","className":["May 31, 2020"],"title":"green","6":"Training, N/A, COVID-19","id":38},{"group":["NCT04276688"],"end":"2020-02-10","className":["July 31, 2022"],"title":"red","6":"Study group, Phase 2, Novel Coronavirus Infection","id":39},{"group":["NCT04276896"],"end":"2020-03-24","className":["December 31, 2024"],"title":"green","6":"pathogen-specific DC and CTLs, Phase 1/Phase 2, Pathogen Infection Covid-19 Infection","id":40},{"group":["NCT04276987"],"end":"2020-02-15","className":["July 31, 2020"],"title":"green","6":"MSCs-derived Exosomes Treatment Group, Phase 1, Coronavirus","id":41},{"group":["NCT04278963"],"end":"2020-02-27","className":["January 2021"],"title":"green","6":"Yin Hu Qing Wen Decoction Group, Phase 2/Phase 3, CoVID-19","id":42},{"group":["NCT04278963"],"end":"2020-02-27","className":["January 2021"],"title":"green","6":"Yin Hu Qing Wen Decoction Group, Phase 2/Phase 3, Chinese Medicine","id":43},{"group":["NCT04279782"],"end":"2020-01-20","className":["February 28, 2021"],"title":"green","6":"Exclusion group, N/A, Coronavirus","id":44},{"group":["NCT04279795"],"end":"2020-01-20","className":["February 28, 2021"],"title":"green","6":"NULL, N/A, Coronavirus","id":45},{"group":["NCT04279899"],"end":"2020-02-01","className":["December 31, 2020"],"title":"green","6":"NULL, N/A, Neonatal Infection","id":46},{"group":["NCT04279899"],"end":"2020-02-01","className":["December 31, 2020"],"title":"green","6":"NULL, N/A, Perinatal Problems","id":47},{"group":["NCT04279899"],"end":"2020-02-01","className":["December 31, 2020"],"title":"green","6":"NULL, N/A, Infectious Disease","id":48},{"group":["NCT04280224"],"end":"2020-02-20","className":["December 30, 2020"],"title":"green","6":"NK Cells Treatment Group, Phase 1, Novel Coronavirus Pneumonia","id":49},{"group":["NCT04280588"],"end":"2020-02-22","className":["July 1, 2020"],"title":"red","6":"Treatment group, Phase 2, Coronavirus Disease (COVID-19)","id":50},{"group":["NCT04280705"],"end":"2020-02-21","className":["April 1, 2023"],"title":"red","6":"Placebo, Phase 2, Corona Virus Infection","id":51},{"group":["NCT04280913"],"end":"2020-02-22","className":["March 31, 2020"],"title":"green","6":"COVID-19 patients, N/A, Coronavirus Disease 2019","id":52},{"group":["NCT04281693"],"end":"2020-02-01","className":["March 2020"],"title":"green","6":"Screening participants, N/A, Novel Coronavirus Infection Pneumonia","id":53},{"group":["NCT04282902"],"end":"2020-02-04","className":["June 1, 2020"],"title":"blue","6":"Pirfenidone group, Phase 3, Novel Coronavirus Pneumonia","id":54},{"group":["NCT04282902"],"end":"2020-02-04","className":["June 1, 2020"],"title":"blue","6":"Pirfenidone group, Phase 3, Pneumonia","id":55},{"group":["NCT04282902"],"end":"2020-02-04","className":["June 1, 2020"],"title":"blue","6":"Pirfenidone group, Phase 3, Pirfenidone","id":56},{"group":["NCT04283396"],"end":"2020-02-21","className":["July 30, 2020"],"title":"green","6":"NULL, N/A, Novel Coronavirus Pneumonia","id":57},{"group":["NCT04283461"],"end":"2020-03-03","className":["June 1, 2021"],"title":"green","6":"Arm 1, Phase 1, Corona Virus Infection","id":58},{"group":["NCT04283825"],"end":"2020-02-22","className":["May 15, 2020"],"title":"green","6":"Humanistic care, N/A, Coronavirus Disease 2019","id":59},{"group":["NCT04283838"],"end":"2020-02-22","className":["May 15, 2020"],"title":"green","6":"Humanistic care, N/A, Coronavirus Disease 2019","id":60},{"group":["NCT04285190"],"end":"2020-02-26","className":["September 15, 2020"],"title":"green","6":"The T89 treatment group, N/A, Coronavirus Disease 2019","id":61},{"group":["NCT04285190"],"end":"2020-02-26","className":["September 15, 2020"],"title":"green","6":"The T89 treatment group, N/A, Novel Coronavirus Pneumonia","id":62},{"group":["NCT04285801"],"end":"2020-02-14","className":["February 25, 2020"],"title":"green","6":"COVID-19 infection, N/A, COVID-19","id":63},{"group":["NCT04286503"],"end":"2020-02-23","className":["February 28, 2021"],"title":"green","6":"Carrimycin, Phase 4, Novel Coronavirus Infectious Disease (COVID-19)","id":64},{"group":["NCT04287686"],"end":"2020-02-01","className":["April 2020"],"title":"green","6":"rhACE2 group, N/A, COVID-19","id":65},{"group":["NCT04288102"],"end":"2020-03-05","className":["December 31, 2021"],"title":"green","6":"Mesenchymal Stem Cells (MSCs), Phase 1/Phase 2, Corona Virus Disease 2019(COVID-19)","id":66},{"group":["NCT04290858"],"end":"2020-03-01","className":["February 1, 2022"],"title":"red","6":"Nitric Oxide inhalation, Phase 2, Coronavirus Infections","id":67},{"group":["NCT04290858"],"end":"2020-03-01","className":["February 1, 2022"],"title":"red","6":"Nitric Oxide inhalation, Phase 2, Pneumonia, Viral","id":68},{"group":["NCT04290858"],"end":"2020-03-01","className":["February 1, 2022"],"title":"red","6":"Nitric Oxide inhalation, Phase 2, Dyspnea","id":69},{"group":["NCT04290871"],"end":"2020-03-01","className":["March 1, 2022"],"title":"red","6":"Treatment Group, Phase 2, Coronavirus","id":70},{"group":["NCT04290871"],"end":"2020-03-01","className":["March 1, 2022"],"title":"red","6":"Treatment Group, Phase 2, SARS (Severe Acute Respiratory Syndrome)","id":71},{"group":["NCT04291053"],"end":"2020-04-01","className":["September 1, 2020"],"title":"green","6":"experimental group, Phase 2/Phase 3, COVID-19","id":72},{"group":["NCT04291729"],"end":"2020-02-17","className":["April 30, 2020"],"title":"green","6":"Ganovo+ritonavir with or without interferon atomization, Phase 4, 2019-nCoV Pneumonia","id":73},{"group":["NCT04292327"],"end":"2020-01-01","className":["July 31, 2020"],"title":"green","6":"The ordinary COVID-19, N/A, Pneumonia Caused by Human Coronavirus","id":74},{"group":["NCT04292340"],"end":"2020-02-01","className":["December 31, 2020"],"title":"green","6":"NULL, N/A, Coronavirus","id":75},{"group":["NCT04292730"],"end":"2020-03-15","className":["May 2020"],"title":"blue","6":"Remdesivir (RDV), 5 Days, Phase 3, COVID-19","id":76},{"group":["NCT04292899"],"end":"2020-03-06","className":["May 2020"],"title":"blue","6":"Remdesivir (RDV), 5 Days, Phase 3, COVID-19","id":77},{"group":["NCT04292964"],"end":"2020-03-01","className":["March 13, 2020"],"title":"green","6":"NULL, N/A, SARS-CoV-2","id":78},{"group":["NCT04292964"],"end":"2020-03-01","className":["March 13, 2020"],"title":"green","6":"NULL, N/A, Outcome, Fatal","id":79},{"group":["NCT04293692"],"end":"2020-02-24","className":["February 25, 2020"],"title":"green","6":"UC-MSCs treatment group, N/A, COVID-19","id":80},{"group":["NCT04293887"],"end":"2020-03-01","className":["June 30, 2020"],"title":"green","6":"Standard therapy + interferon therapy, Early Phase 1, COVID-19","id":81},{"group":["NCT04293887"],"end":"2020-03-01","className":["June 30, 2020"],"title":"green","6":"Standard therapy + interferon therapy, Early Phase 1, Recombinant Human Interferon <U+03B1>1ß","id":82},{"group":["NCT04295551"],"end":"2020-03-14","className":["April 14, 2021"],"title":"green","6":"Experimental group of ordinary COVID-19, N/A, COVID-19","id":83},{"group":["NCT04296643"],"end":"2020-04-01","className":["January 1, 2021"],"title":"green","6":"Medical Mask, N/A, Coronavirus","id":84},{"group":["NCT04296643"],"end":"2020-04-01","className":["January 1, 2021"],"title":"green","6":"Medical Mask, N/A, N95","id":85},{"group":["NCT04296643"],"end":"2020-04-01","className":["January 1, 2021"],"title":"green","6":"Medical Mask, N/A, Medical Mask","id":86},{"group":["NCT04298814"],"end":"2020-03-07","className":["July 30, 2020"],"title":"green","6":"NULL, N/A, COVID-19","id":87},{"group":["NCT04298814"],"end":"2020-03-07","className":["July 30, 2020"],"title":"green","6":"NULL, N/A, Endotracheal Intubation","id":88},{"group":["NCT04299152"],"end":"2020-04-10","className":["November 10, 2020"],"title":"red","6":"Stem Cell Educator therapy treat patients with SARS-CoV-2, Phase 2, Severe Acute Respiratory Syndrome (SARS) Pneumonia","id":89},{"group":["NCT04299711"],"end":"2020-10-15","className":["March 15, 2022"],"title":"green","6":"Baseline, N/A, Mental Disorder","id":90},{"group":["NCT04299724"],"end":"2020-02-15","className":["December 31, 2024"],"title":"green","6":"Injection of Covid-19/aAPC vaccine, Phase 1, Treat and Prevent Covid-19 Infection","id":91},{"group":["NCT04302519"],"end":"2020-03-05","className":["July 30, 2021"],"title":"green","6":"Pulp mesenchymal stem cells, Early Phase 1, COVID-19","id":92},{"group":["NCT04303299"],"end":"2020-03-15","className":["November 30, 2020"],"title":"blue","6":"Oseltamivir plus Chloroquin in Mild COVID19, Phase 3, Coronavirus Infections","id":93},{"group":["NCT04303299"],"end":"2020-03-15","className":["November 30, 2020"],"title":"blue","6":"Oseltamivir plus Chloroquin in Mild COVID19, Phase 3, COVID19","id":94},{"group":["NCT04303507"],"end":"2020-05-01","className":["May 2022"],"title":"green","6":"Chloroquine, N/A, COVID19","id":95},{"group":["NCT04303507"],"end":"2020-05-01","className":["May 2022"],"title":"green","6":"Chloroquine, N/A, Coronavirus","id":96},{"group":["NCT04303507"],"end":"2020-05-01","className":["May 2022"],"title":"green","6":"Chloroquine, N/A, Acute Respiratory Illnesses","id":97},{"group":["NCT04304053"],"end":"2020-03-15","className":["July 15, 2020"],"title":"blue","6":"No Intervention- SARS-CoV-2 surveillance, Phase 3, COVID-19","id":98},{"group":["NCT04304313"],"end":"2020-02-09","className":["November 9, 2020"],"title":"blue","6":"Sildenafil citrate tablets, Phase 3, COVID-19","id":99},{"group":["NCT04305106"],"end":"2020-03-12","className":["May 31, 2020"],"title":"green","6":"Bevacizumab Group, N/A, COVID-19 Pneumonia","id":100},{"group":["NCT04305457"],"end":"2020-03-13","className":["April 1, 2022"],"title":"red","6":"Nitric Oxide inhalation, Phase 2, Coronavirus Infections","id":101},{"group":["NCT04305457"],"end":"2020-03-13","className":["April 1, 2022"],"title":"red","6":"Nitric Oxide inhalation, Phase 2, Pneumonia, Viral","id":102},{"group":["NCT04305457"],"end":"2020-03-13","className":["April 1, 2022"],"title":"red","6":"Nitric Oxide inhalation, Phase 2, Acute Respiratory Distress Syndrome","id":103},{"group":["NCT04305574"],"end":"2020-03-08","className":["May 31, 2020"],"title":"green","6":"Community sample, N/A, Coronavirus","id":104},{"group":["NCT04305574"],"end":"2020-03-08","className":["May 31, 2020"],"title":"green","6":"Community sample, N/A, Depression","id":105},{"group":["NCT04305574"],"end":"2020-03-08","className":["May 31, 2020"],"title":"green","6":"Community sample, N/A, Anxiety","id":106},{"group":["NCT04305574"],"end":"2020-03-08","className":["May 31, 2020"],"title":"green","6":"Community sample, N/A, Stress","id":107},{"group":["NCT04306055"],"end":"2020-03-12","className":["April 9, 2020"],"title":"green","6":"Questionnaire with precaution information, N/A, Blood Donation","id":108},{"group":["NCT04306393"],"end":"2020-03-10","className":["March 10, 2022"],"title":"red","6":"Treatment Group, Phase 2, SARS (Severe Acute Respiratory Syndrome)","id":109},{"group":["NCT04306393"],"end":"2020-03-10","className":["March 10, 2022"],"title":"red","6":"Treatment Group, Phase 2, Coronavirus","id":110},{"group":["NCT04306497"],"end":"2020-03-02","className":["May 2020"],"title":"green","6":"Cohort of western medicine, N/A, COVID-19","id":111},{"group":["NCT04306705"],"end":"2020-02-20","className":["June 20, 2020"],"title":"green","6":"Tocilizumab, N/A, Covid-19","id":112},{"group":["NCT04306705"],"end":"2020-02-20","className":["June 20, 2020"],"title":"green","6":"Tocilizumab, N/A, SARS","id":113},{"group":["NCT04306705"],"end":"2020-02-20","className":["June 20, 2020"],"title":"green","6":"Tocilizumab, N/A, Cytokine Storm","id":114},{"group":["NCT04306705"],"end":"2020-02-20","className":["June 20, 2020"],"title":"green","6":"Tocilizumab, N/A, Cytokine Release Syndrome","id":115},{"group":["NCT04306705"],"end":"2020-02-20","className":["June 20, 2020"],"title":"green","6":"Tocilizumab, N/A, Tocilizumab","id":116},{"group":["NCT04307459"],"end":"2020-03-19","className":["December 31, 2020"],"title":"green","6":"Coronavirus Infection, N/A, Coronavirus Infections","id":117},{"group":["NCT04307459"],"end":"2020-03-19","className":["December 31, 2020"],"title":"green","6":"Coronavirus Infection, N/A, Respiratory Failure","id":118},{"group":["NCT04307459"],"end":"2020-03-19","className":["December 31, 2020"],"title":"green","6":"Coronavirus Infection, N/A, Ventilator Lung","id":119},{"group":["NCT04307693"],"end":"2020-03-11","className":["May 2020"],"title":"red","6":"Lopinavir/ritonavir, Phase 2, COVID-19","id":120},{"group":["NCT04308187"],"end":"2020-03-11","className":["March 2022"],"title":"green","6":"NULL, N/A, Stress, Psychological","id":121},{"group":["NCT04308317"],"end":"2020-03-05","className":["May 1, 2021"],"title":"green","6":"Tetrandrine Cohort, Phase 4, Corona Virus Disease 2019,COVID-19","id":122},{"group":["NCT04308668"],"end":"2020-03-17","className":["May 2021"],"title":"green","6":"Treatment, Phase 2/Phase 3, Corona Virus Infection","id":123},{"group":["NCT04308668"],"end":"2020-03-17","className":["May 2021"],"title":"green","6":"Treatment, Phase 2/Phase 3, Acute Respiratory Distress Syndrome","id":124},{"group":["NCT04308668"],"end":"2020-03-17","className":["May 2021"],"title":"green","6":"Treatment, Phase 2/Phase 3, SARS-CoV Infection","id":125},{"group":["NCT04310228"],"end":"2020-03-08","className":["May 2020"],"title":"green","6":"Favipiravir Combined With Tocilizumab group, N/A, COVID-19","id":126},{"group":["NCT04310865"],"end":"2020-03-20","className":["June 30, 2021"],"title":"green","6":"Yinhu Qingwen Granula Group, Phase 2/Phase 3, COVID-19","id":127},{"group":["NCT04310865"],"end":"2020-03-20","className":["June 30, 2021"],"title":"green","6":"Yinhu Qingwen Granula Group, Phase 2/Phase 3, Severe Pneumonia","id":128},{"group":["NCT04310865"],"end":"2020-03-20","className":["June 30, 2021"],"title":"green","6":"Yinhu Qingwen Granula Group, Phase 2/Phase 3, Chinese Medicine","id":129},{"group":["NCT04311177"],"end":"2020-03-16","className":["April 1, 2021"],"title":"red","6":"Losartan, Phase 2, Corona Virus Infection","id":130},{"group":["NCT04311177"],"end":"2020-03-16","className":["April 1, 2021"],"title":"red","6":"Losartan, Phase 2, Acute Respiratory Distress Syndrome","id":131},{"group":["NCT04311177"],"end":"2020-03-16","className":["April 1, 2021"],"title":"red","6":"Losartan, Phase 2, SARS-CoV Infection","id":132},{"group":["NCT04311398"],"end":"2020-03-14","className":["December 1, 2020"],"title":"green","6":"Respiratory infection group, N/A, COVID-19","id":133},{"group":["NCT04311697"],"end":"2020-04-01","className":["September 2020"],"title":"red","6":"Aviptadil IV followed by IV + Nebulization, Phase 2, Acute Respiratory Distress Syndrome","id":134},{"group":["NCT04311697"],"end":"2020-04-01","className":["September 2020"],"title":"red","6":"Aviptadil IV followed by IV + Nebulization, Phase 2, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)","id":135},{"group":["NCT04311697"],"end":"2020-04-01","className":["September 2020"],"title":"red","6":"Aviptadil IV followed by IV + Nebulization, Phase 2, Corona Virus Infection","id":136},{"group":["NCT04312009"],"end":"2020-03-16","className":["April 1, 2021"],"title":"red","6":"Losartan, Phase 2, Corona Virus Infection","id":137},{"group":["NCT04312009"],"end":"2020-03-16","className":["April 1, 2021"],"title":"red","6":"Losartan, Phase 2, Acute Respiratory Distress Syndrome","id":138},{"group":["NCT04312009"],"end":"2020-03-16","className":["April 1, 2021"],"title":"red","6":"Losartan, Phase 2, SARS-CoV Infection","id":139},{"group":["NCT04312100"],"end":"2020-02-01","className":["February 2021"],"title":"green","6":"Mild cases with conventional oxygen therapy, N/A, Coronavirus Disease-2019","id":140},{"group":["NCT04312243"],"end":"2020-03-20","className":["March 20, 2022"],"title":"red","6":"Treatment Group, Phase 2, Coronavirus Infections","id":141},{"group":["NCT04312243"],"end":"2020-03-20","className":["March 20, 2022"],"title":"red","6":"Treatment Group, Phase 2, Healthcare Associated Infection","id":142},{"group":["NCT04312464"],"end":"2020-01-01","className":["March 18, 2020"],"title":"green","6":"Discharged group, N/A, COVID-19","id":143},{"group":["NCT04312464"],"end":"2020-01-01","className":["March 18, 2020"],"title":"green","6":"Discharged group, N/A, Cardiovascular Diseases","id":144},{"group":["NCT04312997"],"end":"2020-04-01","className":["October 2020"],"title":"red","6":"PUL-042 Inhalation Solution, Phase 2, COVID-19","id":145},{"group":["NCT04313023"],"end":"2020-04-01","className":["October 2020"],"title":"red","6":"PUL-042 Inhalation Solution, Phase 2, COVID-19","id":146},{"group":["NCT04313127"],"end":"2020-03-19","className":["December 20, 2022"],"title":"green","6":"Low-dose Group, Phase 1, COVID-19","id":147},{"group":["NCT04313322"],"end":"2020-03-16","className":["September 30, 2020"],"title":"green","6":"WJ-MSCs, Phase 1, Use of Stem Cells for COVID-19 Treatment","id":148},{"group":["NCT04313946"],"end":"2020-03-18","className":["August 18, 2020"],"title":"green","6":"Symptomatic Patients, N/A, COVID-19","id":149},{"group":["NCT04313946"],"end":"2020-03-18","className":["August 18, 2020"],"title":"green","6":"Symptomatic Patients, N/A, Pneumonia, Viral","id":150},{"group":["NCT04313946"],"end":"2020-03-18","className":["August 18, 2020"],"title":"green","6":"Symptomatic Patients, N/A, Influenza With Pneumonia","id":151},{"group":["NCT04313946"],"end":"2020-03-18","className":["August 18, 2020"],"title":"green","6":"Symptomatic Patients, N/A, Flu Symptom","id":152},{"group":["NCT04313946"],"end":"2020-03-18","className":["August 18, 2020"],"title":"green","6":"Symptomatic Patients, N/A, Flu Like Illness","id":153},{"group":["NCT04313946"],"end":"2020-03-18","className":["August 18, 2020"],"title":"green","6":"Symptomatic Patients, N/A, Pneumonia, Interstitial","id":154},{"group":["NCT04313946"],"end":"2020-03-18","className":["August 18, 2020"],"title":"green","6":"Symptomatic Patients, N/A, Pneumonia, Ventilator-Associated","id":155},{"group":["NCT04313946"],"end":"2020-03-18","className":["August 18, 2020"],"title":"green","6":"Symptomatic Patients, N/A, Pneumonia Atypical","id":156},{"group":["NCT04314232"],"end":"2020-03-23","className":["December 31, 2021"],"title":"green","6":"NULL, N/A, Coronavirus","id":157},{"group":["NCT04314232"],"end":"2020-03-23","className":["December 31, 2021"],"title":"green","6":"NULL, N/A, SARS","id":158},{"group":["NCT04314271"],"end":"2020-03-20","className":["May 31, 2020"],"title":"green","6":"NULL, N/A, Novel Coronavirus Pneumonia","id":159},{"group":["NCT04314817"],"end":"2020-03-17","className":["January 1, 2023"],"title":"green","6":"Patients treated for Covid-19, N/A, Coronavirus","id":160},{"group":["NCT04314817"],"end":"2020-03-17","className":["January 1, 2023"],"title":"green","6":"Patients treated for Covid-19, N/A, Iatrogenic Disease","id":161},{"group":["NCT04314817"],"end":"2020-03-17","className":["January 1, 2023"],"title":"green","6":"Patients treated for Covid-19, N/A, Acute Kidney Injury","id":162},{"group":["NCT04314817"],"end":"2020-03-17","className":["January 1, 2023"],"title":"green","6":"Patients treated for Covid-19, N/A, ARDS, Human","id":163},{"group":["NCT04315298"],"end":"2020-03-16","className":["March 16, 2021"],"title":"green","6":"Sarilumab high dose, Phase 2/Phase 3, COVID-19","id":164},{"group":["NCT04315870"],"end":"2020-01-01","className":["April 30, 2020"],"title":"green","6":"NULL, N/A, Infection Viral","id":165},{"group":["NCT04315896"],"end":"2020-03-23","className":["March 22, 2021"],"title":"blue","6":"treatment, Phase 3, COVID-19","id":166},{"group":["NCT04315896"],"end":"2020-03-23","className":["March 22, 2021"],"title":"blue","6":"treatment, Phase 3, Severe Acute Respiratory Syndrome","id":167},{"group":["NCT04315948"],"end":"2020-03-01","className":["March 2023"],"title":"blue","6":"Remdesivir, Phase 3, Corona Virus Infection","id":168},{"group":["NCT04315987"],"end":"2020-04-01","className":["June 2020"],"title":"green","6":"NestCell®, Phase 1, COVID-19 Pneumonia","id":169},{"group":["NCT04316299"],"end":"2020-02-26","className":["March 8, 2020"],"title":"green","6":"AKI, N/A, COVID-19","id":170},{"group":["NCT04316299"],"end":"2020-02-26","className":["March 8, 2020"],"title":"green","6":"AKI, N/A, Acute Kidney Injury","id":171},{"group":["NCT04316299"],"end":"2020-02-26","className":["March 8, 2020"],"title":"green","6":"AKI, N/A, Kidney Function","id":172},{"group":["NCT04316377"],"end":"2020-03-23","className":["March 3, 2025"],"title":"green","6":"Treatment, Phase 4, Corona Virus Infection","id":173},{"group":["NCT04316728"],"end":"2020-03-01","className":["November 2020"],"title":"green","6":"negative Patients, N/A, Coronavirus Infections","id":174},{"group":["NCT04316884"],"end":"2020-03-12","className":["December 31, 2021"],"title":"green","6":"COVID-19, N/A, COVID-19","id":175},{"group":["NCT04316884"],"end":"2020-03-12","className":["December 31, 2021"],"title":"green","6":"COVID-19, N/A, Organ Dysfunction Syndrome Sepsis","id":176},{"group":["NCT04316884"],"end":"2020-03-12","className":["December 31, 2021"],"title":"green","6":"COVID-19, N/A, Organ Dysfunction Syndrome, Multiple","id":177},{"group":["NCT04316884"],"end":"2020-03-12","className":["December 31, 2021"],"title":"green","6":"COVID-19, N/A, Septic Shock","id":178},{"group":["NCT04316884"],"end":"2020-03-12","className":["December 31, 2021"],"title":"green","6":"COVID-19, N/A, Acute Kidney Injury","id":179},{"group":["NCT04316884"],"end":"2020-03-12","className":["December 31, 2021"],"title":"green","6":"COVID-19, N/A, Acute Respiratory Distress Syndrome","id":180},{"group":["NCT04317040"],"end":"2020-05-01","className":["May 2022"],"title":"blue","6":"CD24Fc Treatment, Phase 3, Severe Coronavirus Disease (COVID-19)","id":181},{"group":["NCT04317092"],"end":"2020-03-19","className":["December 19, 2022"],"title":"red","6":"tocilizumab treatment, Phase 2, COVID-19 Pneumonia","id":182}]
